# Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

> **NCT00425308** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Everolimus + Cyclosporine
- **DRUG:** Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)
- **DRUG:** Steroids

## Key facts

- **NCT ID:** NCT00425308
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-05
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425308, "Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00425308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*